1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
MultiCell Technologies, Inc.

MultiCell Technologies, Inc.

MCET
MultiCell Technologies, Inc.US flagOther OTC
0.00
USD
- -
- -
50,009.00Market Cap
2002 Y
2003 Y
2004 Y
2005 Y
2006 Y
2007 Y
2008 Y
2009 Y
2010 Y
2011 Y
2012 Y
2013 Y
2014 Y
TTM
Revenue per Share
0.04
0.02
0.03
0.01
0.02
0.01
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
-0.08
-0.09
-0.12
-0.18
-0.2
-0.07
-0.04
- -
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
-0.04
0.02
-0.06
-0.1
-0.13
-0.01
-0.01
-0.01
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-0.72
-0.76
-0.82
-0.83
-0.93
-0.81
-0.59
-0.19
-0.09
-0.05
-0.03
-0.01
- -
- -
Tangible Book Value per Share
-0.09
-0.08
0.02
0.06
-0.07
-0.08
-0.08
-0.02
-0.01
-0.01
- -
- -
- -
- -
Basic Weighted Avg Shares
20
21
24
31
35
44
64
187
380
693
1,035
1,916
3,726
4,885
Sales/Revenue/Turnover
1
- -
1
- -
1
- -
- -
- -
- -
- -
- -
- -
- -
1
Operating Margin (%)
-178.58
-440.54
-197.59
-2,880.9
-886.83
-1,246.75
-490.68
-467.59
-1,795.13
-4,687.66
-3,193.28
-2,773.89
-1,465.6
-59.6
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
-2
-2
-1
-6
-5
-3
-2
-1
-1
-2
-1
-1
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-195.97
-543.33
-164.53
-2,717.09
-796.94
-1,260
-998.37
-433.98
-1,180.38
-3,651.12
-2,547.24
-2,503.38
-770.65
-31.49
Working Capital
-1
-1
1
2
-1
-1
-2
-1
-1
-1
-1
-1
-1
-1
LT Debt
1
1
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
1
- -
2
3
-1
-3
-2
-2
-2
-2
-2
-2
-2
-2
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-3.98
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Feb'15
May'15
Aug'15
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
4,863
5,001
5,001
Market Capitalization
1
2
1

Working Capital

FRC

•

in mil. unless spec.
Feb'15
May'15
Aug'15
Total Current Assets
- -
- -
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
1
1
2
Payables & Accruals
1
1
1
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-6.61%
-1.74%
-3.21%
Free Cash Flow
24.69%
11.03%
-13.01%
Net Income, GAAP
21.8%
1.49%
-69.22%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2013
- -
- -
- -
- -
- -
2014
- -
- -
- -
- -
- -
2015
- -
1
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2013
- -
- -
- -
- -
- -
2014
- -
- -
- -
- -
- -
2015
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2013
- -
- -
- -
- -
- -
2014
- -
- -
- -
- -
- -
2015
- -
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
W. Gerald Newmin
Full Time Employees
2
Sector
Healthcare
Industry
Biotechnology
Address
68 Cumberland Street Woonsocket RI United States of America 02895
IPO Date
Jan 3, 2000
CIK
0000811779
Website
multicelltech.com
Similar Companies
Sage Therapeutics, Inc. (SAGE)
ChitogenX Inc. (CHNXF)
Annexon, Inc. (ANNX)
TheraVet S.A. (ALVET.PA)
Sorrento Therapeutics, Inc. (SRNEQ)
Nascent Biotech, Inc. (NBIO)
Business
MultiCell Technologies, Inc. is a clinical-stage biopharmaceutical company engaged in the development of novel therapeutics and discovery tools aimed at addressing unmet medical needs in neurological disorders, hepatic diseases, and cancer. The company’s therapeutic development platform includes patented methods to isolate, characterize, and differentiate stem cells derived from human liver and to modulate immune responses at transcriptional and translational levels using dsRNA-sensing molecules such as Toll-like receptors, RIG-I-like receptors, and MDA-5 signaling pathways. MultiCell produces specialized cell lines used by pharmaceutical companies for drug screening and development. Its core products and services encompass stem cell-based research tools and therapeutic candidates targeting inflammatory, viral, and oncological conditions. Founded in 1970 and headquartered in Dallas, Texas, MultiCell has recently undertaken strategic advancements including the acquisition of intellectual property and equipment from Astral Inc., enhancing its capabilities in developing novel therapeutics particularly for autoimmune diseases and cancer. The company has also formed a majority-owned subsidiary, Monticello Immunotherapeutics, to leverage its human hepatocyte lines and advance therapeutic development independently. MultiCell entered into a research and development and product licensing agreement with Oxis Biotech to create antibody-drug conjugates (ADCs) for targeted treatment of triple-negative breast cancer and multiple myeloma. This agreement includes milestone payments and options for manufacturing rights, marking a significant expansion into ADC therapeutics. These recent moves underscore a strategic shift towards strengthening their biopharmaceutical pipeline and expanding partnerships to commercialize innovative drug candidates on a broader scale. MultiCell's operations and development focus are primarily within the United States but oriented towards global pharmaceutical collaborations. The company's portfolio reflects integration of its patented stem cell technologies with immunomodulatory therapeutic development, positioning MultiCell in the biotechnology and pharmaceutical sector as a specialist in novel treatment modalities through advanced cellular and molecular platforms.